Espira's objective is to develop rapid and inexpensive microfluidics-based tools for clinical and environmental applications.  Espira has developed several technologies for sample preparation, amplification and detection:

(i) detect and quantify rare nucleic acid mutations by microfluidic digital polymerase chain reaction (PCR),

(ii) automated glass-fiber based nucleotide extraction,

(iii) rapid PCR using temperature gradient continuous flow PCR